Stock Code: 300937
Stock Abbreviation: Yaogou
Announcement No.: 2026-029
Sichuan Hezhong Yaogou Pharmaceutical Co., Ltd.
Announcement on Abnormal Stock Trading Fluctuations
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Special Reminder:
-
The closing price of Sichuan Hezhong Yaogou Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") stock has deviated significantly for three consecutive trading days from July 13, 2026, to July 15, 2026, with a cumulative increase exceeding 30%. According to the "Trading Rules of the Shenzhen Stock Exchange," this constitutes abnormal stock trading fluctuations.
-
The Company's operating revenue for 2025 was RMB 445,400.15 million, a year-on-year increase of 1.35% after adjustment. The net profit attributable to shareholders of the listed company was RMB -1,285.15 million, a year-on-year decrease of 197.36% after adjustment. For details, please refer to the "2025 Annual Report" disclosed by the Company on April 29, 2026. The operating revenue for the first quarter of 2026 was RMB 111,392.06 million, a year-on-year decrease of 2.08%. The net profit attributable to shareholders of the listed company was RMB -272.02 million, a year-on-year decrease of 165.02%. For details, please refer to the "2026 First Quarterly Report" disclosed by the Company on April 29, 2026. Due to the continuous promotion of national centralized drug procurement policies and other factors, the pharmaceutical distribution industry faces significant competitive pressure, industry profit margins are compressed, subsidiary promotion costs have increased, tax incentives have been canceled, deferred tax assets have been reversed, investment accounting has been corrected, and goodwill impairment has occurred. These multiple factors have led to a decline in the Company's performance during the period, and future profitability is uncertain.
-
On April 29, 2026, the Company disclosed the "2025 Annual Report," "2025 Audit Report," and "2025 Internal Control Audit Report." Xinyongzhonghe Certified Public Accountants (Special General Partnership) issued a qualified opinion in the "2025 Audit Report" and an unqualified opinion with an emphasis of matter in the "2025 Internal Control Audit Report." The Company further disclosed the "Special Explanation of the Board of Directors and Audit Committee on the Correction of Previous Accounting Errors," "Special Explanation of Xinyongzhonghe Certified Public Accountants Regarding the Qualified Audit Opinion on the Company's 2025 Financial Statements," and the "Notice Regarding the Delayed Disclosure of Financial Information After Correction of Accounting Errors," etc.